More than 90% of patients achieved clinically meaningful weight reduction compared to placebo in a phase 3 trial of ecnoglutide.

A novel weight loss drug in the same class as semaglutide has successfully met its targets in its largest clinical trial yet, ...

BARCELONA -- A rheumatology trainee who went on TikTok to find information on her own condition may have uncovered a novel ...

A common diabetes drug may be the next big thing for migraine relief. In a clinical study, obese patients with chronic ...

New research links semaglutide and tirzepatide, which are GLP-1 agonists used to treat type 2 diabetes and aid weight loss, ...

Patients with type 2 diabetes had a lower risk of glaucoma when they used glucagon-like peptide 1 (GLP-1) receptor agonists across multiple studies.

Real-world cost barriers and insurance denials contribute to early discontinuation of injectable glucagon-like peptide-1 (GLP ...

A diabetes medication that lowers brain fluid pressure has cut monthly migraine days by more than half, according to a new ...

A diabetes medication that lowers brain fluid pressure has cut monthly migraine days by more than half, according to a new ...

To circumvent this, we have expanded our understanding of the structure activity relationship of ASOs conjugated to Glucagon Like Peptide 1 Receptor (GLP1R) agonist peptide ligands. We demonstrate the ...

Discover how GLP-1 drugs are driving demand for new supplements. Insights from Vitafoods Europe 2025 reveal how the industry ...

If you’re considering using medication to reach a healthy body weight, your first question might be: Are weight loss drugs covered by insurance? The short answer: Sometimes, but not always.